Loading page…

Report overview

The report describes the Pharma Mar Group's €77 million investment in R&D in 2017 and its research pipeline in oncology and ophthalmology. It reports 727 employees at year-end and highlights training, equality planning and workplace safety programmes. Environmentally, PharmaMar and Xylazel were certified to ISO 14001, while the Group reported no environmental incidents or sanctions during the year.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2017
Language
Pages
File size

Standards & Assurance

Standards

Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Assurance

Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Energy consumption
Water consumption
Employees
Women on the board
Women in management

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services

Corporate Social Responsibility Report

Report overview

Document

Standards & Assurance

Standards

Commitments

Assurance

ESG & Materiality

ESG data

Materiality

Build your research dataset.

Corporate Social Responsibility Report

Report overview

Document

Standards & Assurance

Standards

Commitments

Assurance

ESG & Materiality

ESG data

Materiality

Build your research dataset.